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Abstract
Purpose Previous studies suggest that anterior mitral valve leaflet (AMVL) elongation is a primary phenotypic feature in 
hypertrophic cardiomyopathy (HCM). Our aim was to assess AMVL length in individuals with HCM gene mutations and 
in healthy controls and to identify predictors of the development of HCM during follow-up.
Methods A total of 133 HCM mutation carriers and 135 controls underwent cardiac examination including electro- and 
echocardiography. AMVL length was measured in the parasternal long axis and apical three chamber view during diastole. 
Univariate and multivariable cox proportional hazard regression analyses were performed to identify predictors of HCM.
Results There were no significant differences between HCM mutation carriers and controls regarding age and sex. In the 
parasternal long axis view, AMVL length was similar in mutation carriers and controls (24 ± 4 vs 24 ± 4 mm, p = 0.8). In 
the apical three chamber view, AMVL were shorter in mutation carriers (29 ± 4 vs 30 ± 4 mm, p = 0.02). When averaged for 
both views, AMVL length was similar in mutation carriers and controls (27 ± 3 vs 27 ± 3 mm, p = 0.2). During 5.8 ± 3.0 years 
follow-up, 13 (14%) HCM mutation carriers developed HCM. Pathological Q wave (hazard ratio 9.89, p = 0.004), E/e′ ratio 
(hazard ratio 2.52, p = 0.001), and maximal wall thickness (hazard ratio 2.15, p = 0.001) were independent predictors of 
HCM. AMVL length was not predictive of the development of HCM.
Conclusions AMVL length is similar in HCM mutation carriers and controls. AMVL length is not predictive of the develop-
ment of HCM, in contrast to pathological Q wave, E/e′ ratio, and maximal wall thickness.
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SOMMARIO
Obiettivi Studi precedenti suggeriscono che l’allungamento della cuspide anteriore della valvola mitrale (LAVM) è una 
caratteristica fenotipica primaria nella cardiomiopatia ipertrofica (HCM). Il nostro obiettivo era quello di valutare la lung-
hezza del LAVM in individui con mutazioni del gene HCM e nei controlli sani e di identificare i predittori dello sviluppo 
di HCM durante il follow-up.
Metodi Un totale di 133 portatori di mutazione HCM e 135 controlli sono stati sottoposti ad un esame cardiologico che 
comprendeva un elettrocardiogramma ed ecocardiografia. La lunghezza del LAVM è stata misurata durante la fase diastolica 
in proiezione parasternale asse longitudinale ed in proiezione 3 camere apicali. Le analisi di regressione del rischio propor-
zionale coassiale univariata e multivariata sono state eseguite per identificare I predittori di HCM.
Risultati Non sono risultate differenze significative tra portatori di mutazione HCM e controlli per quanto riguarda età e 
sesso. Nella proiezione parasternale asse lungo, la lunghezza del LAVM era simile nei portatori di mutazione e controlli 
(24 ± 4 vs 24 ± 4 mm, p = 0.8). Nella proiezione 3 camere apicale, i valori del LAVM erano minori nei portatori di mutazione 
(29 ± 4 vs 30 ± 4 mm, p = 0.02). Eseguendo la media dei valori per entrambe le proiezioni, la lunghezza del LAVM era simile 
nei portatori di mutazione e nei controlli (27 ± 3 vs 27 ± 3 mm, p = 0.2). Durante un periodo di follow-up di 5.8 ± 3.0 anni, 
13 (14%) dei portatori della mutazione HCM hanno sviluppato HCM. L’onda Q patologica (hazard ratio 9.89, p = 0,004), il 
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rapporto E/e′ (hazard ratio 2.52, p = 0.001) e lo spessore massimale della parete (hazard ratio 2.15, p = 0.001) sono risultati 
predittori indipendenti di HCM. La lunghezza del LAVM non era predittiva di sviluppo di HCM.
Conclusioni La lunghezza del LAVM è simile nei portatori della mutazione HCM e nei controlli. La lunghezza del LAVM 
non è risultata predittiva dello sviluppo di HCM, a differenza dell’onda Q patologica, del rapporto E/e’, e dello spessore 
massimale della parete.
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic car-
diac disease with an estimated prevalence of 1:500–1:200 
[1–3]. The diagnosis is based on the presence of a maximal 
wall thickness  ≥ 15 mm in index patients and  ≥ 13 mm in 
relatives, that is not solely explained by abnormal loading 
conditions [2]. A pathogenic HCM mutation is identified 
in 40–60% of patients with HCM [2, 4]. Presymptomatic 
genetic testing of relatives has led to the identification of 
HCM gene mutation carriers who do not fulfill the echocar-
diographic criterion of HCM [5]. HCM mutation carriers 
are at risk of developing HCM [5]. Conflicting data exists 
on whether the anterior mitral valve leaflets (AMVL) are 
elongated in mutation carriers and whether AMVL elon-
gation is a predictor of the development of HCM during 
follow-up [6–11]. The aim of this study was to assess AMVL 
length in HCM mutation carriers and healthy controls and 
to determine the prognostic significance of AMVL length in 
HCM mutation carriers for the development of HCM during 
follow-up.
Methods
Study design and population
This single-center retrospective case–control and cohort 
study included 133 HCM mutation carriers without clinical 
expression of HCM who were clinically evaluated at our car-
dio-genetic outpatient clinic between the years 2004–2017. 
Genetic assessment and the family screening strategy at our 
center have been described previously [12, 13]. For com-
parison, 135 healthy controls underwent cardiac evaluation 
[14]. Controls were recruited via an advertisement. Inclu-
sion criteria were normal physical examination, normal elec-
trocardiography (ECG), and left ventricular (LV) ejection 
fraction  > 51%; exclusion criteria were prior cardiovascular 
disease or risk factors consisting of hypertension, diabetes 
mellitus, and hypercholesterolemia, systemic disease, medi-
cation known to influence cardiac function including thyroid 
medication (with the exception of asthma inhalers), profes-
sional athletes, body mass index  > 40 and women with 
breast implants [14]. The study conforms to the principles 
of the Declaration of Helsinki. All patients gave informed 
consent for inclusion in the registry and local institutional 
review board approval was obtained.
Clinical evaluation
Clinical evaluation included medical history, physical exam-
ination, ECG, and transthoracic echocardiography. Standard 
12-lead ECG was performed in the supine position during 
quiet respiration. LV hypertrophy was evaluated with the 
Romhilt–Estes criteria. Pathological Q waves were defined 
as duration  > 40 ms or depth  > 30% R wave in  ≥ 2 leads. T 
wave inversion was defined as  ≥ 3 mm in  ≥ 2 leads. Echo-
cardiographic studies were analyzed according to the guide-
lines [15, 16]. Maximal wall thickness, left atrial size, leaflet 
and chordal systolic anterior motion of the mitral valve, and 
resting LV outflow tract peak velocity were assessed. LV 
outflow tract gradient was calculated with the Bernoulli 
equation. LV systolic function was categorized as: good 
(LV ejection fraction  > 51%), mildly reduced (LV ejection 
fraction 41–51%), moderately reduced (LV ejection fraction 
30–40%), and poor (LV ejection fraction  < 30%) [16]. LV 
diastolic function was defined as normal, abnormal relaxa-
tion, pseudonormal or restrictive filling, based on Doppler 
mitral inflow pattern parameters including early (E) and 
late (A) LV filling velocities, E/A ratio, and tissue Doppler 
imaging-derived septal early diastolic velocities (e′) [17]. 
HCM during follow-up was defined as a maximal wall thick-
ness ≥ 13 mm according to the guidelines [2].
AMVL measurements
AMVL length was measured in the parasternal long axis 
(PLAX) view and in the apical three chamber (A3C) view, 
during diastole and with the leaflet maximally extended. 
In the PLAX view, leaflet length was defined as the dis-
tance from the tip of the leaflet to the junction between the 
anterior leaflet and the posterior aortic wall (hinge point), 
according to Klues et al. [18]. In the A3C view, leaflet length 
was defined as the distance from the tip of the leaflet to 
the insertion of the noncoronary aortic leaflet, according to 
Alhaj et al. [19]. Examples of AMVL measurements in both 
views are shown in Fig. 1. All AMVL measurements were 
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performed by one reader. For intraobserver variability, one 
reader independently measured 40 AMVLs in the PLAX 
view and 40 AMVLs in the A3C view in an identical fashion 
on two occasions. For interobserver variability, two readers 
independently measured 20 AMVLs in the PLAX view and 
20 AMVLs in the A3C view.
Statistical methods
The statistical analysis was performed using SPSS 21 (IBM, 
Armonk, NY). Normally distributed continuous data are 
expressed as mean ± standard deviation and non-normally 
distributed data as median followed by interquartile range. 
For comparing categorical variables Pearson’s Chi-square 
test was used. For comparing continuous variables t test was 
used, and Mann–Whitney U in case of non-normally distrib-
uted data. All analyses were two-sided; p values  < 0.05 were 
considered significant. Inter-observer and intra-observer 
agreement was defined as the mean of the difference between 
two measurements ± standard deviation. Univariate and mul-
tivariable cox proportional hazard regression was performed 
to determine hazard ratios (HR) and 95% confidence inter-
vals (CI). After screening for multicollinearity, the univari-
ate significant variables with the highest HR were entered 
into the multivariable regression model. To calculate the 
allowed number of variables for inclusion in the multivari-
able analysis, the square root of the number of events was 
used. This is an alternative method to determine the num-
ber of variables allowed for inclusion in the multivariable 
analysis [20].
Results
Clinical evaluation
HCM gene mutation carriers represented mutations in 10 
different genes. The MYBPC3 gene was most frequently 
affected (77%), followed by the MYH7 gene (11%). Other 
genes affected were TNNT2 (3%), MYL2 (2%), FHL1 (2%), 
ALPK3 (2%) MIB1 (0.75%), TNNI3 (0.75%), TPM1 (0.75%), 
and MYL3 (0.75%). Clinical and echocardiographic char-
acteristics in mutation carriers and controls are presented 
in Table  1. Mutation carriers and controls had similar 
age, gender, and body surface area. Compared to controls, 
more mutation carriers had pathological Q waves (4 vs 
0%, p = 0.02), and mutation carriers had a higher E/e′ ratio 
(8.2 ± 1.9 vs 7.7 ± 1.9, p = 0.03), and a higher maximal wall 
thickness (8.9 ± 1.9 vs 8.0 ± 1.8 mm, p = 0.001).
AMVL measurements
Beeswarm plots of AMVL measurements in the PLAX and 
the A3C view are presented in Fig. 2. In the PLAX view, 
Fig. 1  Example of anterior mitral valve leaflet length (AMVL) meas-
urements in a hypertrophic cardiomyopathy gene mutation carrier 
without hypertrophic changes. In the parasternal long-axis view, a the 
AMVL measured 26 mm, and in the apical three chamber view, b the 
AMVL measured 26 mm
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AMVL length did not differ between mutation carriers and 
controls (24 ± 4 vs 24 ± 4 mm, p = 0.8). In the A3C view, 
AMVL were shorter in the mutation carriers (29 ± 4 vs 
30 ± 4 mm, p = 0.02). When averaged for both views, AMVL 
length was similar in mutation carriers and controls (27 ± 3 
vs 27 ± 3 mm, p = 0.2). Overall, AMVL were significantly 
Table 1  Clinical and 
echocardiographic 
characteristics of the study 
population
Data are expressed as mean ± standard deviation or as absolute and (%)
AMVL anterior mitral valve leaflet, A3C apical three chamber view, LVOT left ventricular outflow tract, 
PLAX parasternal long-axis view
a at rest
Variable Mutation carrier 
(n = 133)
Control (n = 135) p value
Age (year) 41 ± 14 44 ± 14 0.11
Female gender n (%) 85 (64) 73 (54) 0.18
Body surface area  (m2) 1.9 ± 0.2 1.9 ± 0.2 0.86
Electrocardiography
 Romhilt–Estes ≥ 4 n (%) 10 (8) 4 (3) 0.09
 T wave inversion n (%) 1 (1) 0 (0) 0.31
 Pathological Q wave n (%) 5 (4) 0 (0) 0.02
Echocardiography
 Maximal wall thickness (mm) 8.9 ± 2.0 8.0 ± 1.8 <0.001
 Left atrial size (mm) 34 ± 5 34 ± 4 0.24
 LVOT gradient ≥ 30 mmHga n (%) 0 (0) 0 (0) 0.50
 AMVL, PLAX (mm) 24 ± 4 24 ± 4 0.85
 AMVL, A3C (mm) 29 ± 4 30 ± 4 0.02
 AMVL, averaged (mm) 27 ± 3 27 ± 3 0.17
 Chordal systolic anterior motion n (%) 5 (4) 1 (1) 0.09
 Leaflet systolic anterior motion n (%) 0 (0) 0 (0) 0.50
 E/A ratio 1.4 ± 0.5 1.6 ± 0.7 0.03
 E/e’ ratio 8.2 ± 1.9 7.7 ± 1.9 0.03
 Septal e’ (cm/s) 9.5 ± 2.5 9.6 ± 2.6 0.61
Diastolic function
 Normal n (%) 105 (83) 111 (85) 0.66
 Abnormal relaxation n (%) 10 (8) 7 (5) 0.39
 Pseudonormal filling n (%) 11 (9) 13 (10) 0.76
 Restrictive filling n (%) 0 (0) 0 (0) 0.50
Systolic function
 Good n (%) 132 (99) 135 (100) 0.31
 Mildly reduced n (%) 1 (1) 0 (0) 0.31
 Moderately reduced n (%) 0 (0) 0 (0) 0.50
 Poor n (%) 0 (0) 0 (0) 0.50
Fig. 2  Beeswarm plot of 
anterior mitral valve leaflet 
(AMVL) length measurements 
in hypertrophic cardiomyopathy 
gene mutation carriers without 
hypertrophic changes versus 
healthy controls, assessed with 
transthoracic echocardiography 
in the a parasternal long-axis 
view and b apical three chamber 
view
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longer in the A3C view than in the PLAX view (30 ± 4 vs 
24 ± 4 mm, p < 0.001).
Intra‑observer and inter‑observer agreement
In the PLAX view, the inter-observer agreement was 
− 2.7 ± 2.6  mm and the intra-observer agreement was 
− 1.0 ± 3.5 mm. In the A3C view, the inter-observer agree-
ment was 2.0 ± 2.5 mm and the intra-observer agreement 
was 0.5 ± 2.6 mm.
Follow‑up
During 5.8 ± 3.0 years follow-up, 13 (14%) mutation car-
riers developed HCM. Mean age at HCM diagnosis was 
52 ± 17 years. In these 13 mutation carriers, maximal wall 
thickness increased from a median 10 (interquartile range 8, 
11) mm to 13 (interquartile range 13, 14) mm, with a mean 
rate of 0.7 ± 0.3 mm/year. Table 2 presents the baseline char-
acteristics in those who developed HCM during follow-up 
and those who did not. Univariate significant predictors of 
the development of HCM were pathological Q wave (HR 
9.74, 95% CI 2.53–37.46, p = 0.001), maximal wall thick-
ness (HR 1.64, 95% CI 1.12–2.39, p = 0.01), E/e′ ratio (HR 
1.63, 95% CI 1.20–2.23, p = 0.002), left atrial size (HR 
1.16, 95% CI 1.03–1.31, p = 0.01), and age (HR 1.06, 95% 
CI 1.02–1.11, p = 0.01). AMVL length was not predictive 
of the development of HCM in the PLAX view (HR 1.03, 
95% CI 0.87–1.22, p = 0.72) or in the A3C view (HR 0.99, 
95% CI 0.86–1.15, p = 0.92). Multivariable cox regression 
analysis which included three variables demonstrates that 
pathological Q wave (adjusted HR 9.89, 95% CI 2.09–46.95, 
p = 0.004), E/e′ ratio (adjusted HR 2.52, 95% CI 1.48–4.29, 
p = 0.001), and maximal wall thickness (adjusted HR 2.15, 
95% CI 1.36–3.42, p = 0.001) all were independent predic-
tors of HCM during follow-up.
Discussion
During HCM family screening, individuals who carry a 
HCM gene mutation may not fulfil the echocardiographic 
diagnostic criterion of HCM [5]. Because of the age-related 
penetrance of HCM, long-term clinical follow-up includ-
ing ECG and echocardiography is recommended [2, 3]. 
Currently, it is unclear which HCM mutation carriers will 
develop HCM [2, 11]. We aimed to assess AMVL length in 
mutation carriers and controls, and determine the prognostic 
value of AMVL length for the development of HCM during 
follow-up. Our main findings are: (1) AMVL length is simi-
lar in mutation carriers and controls, (2) AMVL length is not 
predictive of the development of HCM, and (3) pathological 
Q wave, E/e′ ratio, and maximal wall thickness are independ-
ent predictors of the development of HCM.
AMVL elongation is not a primary phenotypic 
feature of HCM
In patients with HCM, AMVL elongation has been dem-
onstrated pathologically, on echocardiography, and on car-
diovascular magnetic resonance imaging [10, 18, 21–23]. 
Among other factors, AMVL elongation contributes to 
systolic anterior motion of the mitral valve and LV outflow 
tract obstruction [23–25]. The etiology of AMVL elonga-
tion in patients with HCM is unclear. Both the pathological 
study of Klues et al. and the in vivo study of Kim et al. 
found that AMVL elongation is not secondary to LV outflow 
tract obstruction or systolic anterior motion of the mitral 
valve, since it also occurs in patients without LV outflow 
tract obstruction or systolic anterior motion [19, 21, 22]. 
Therefore, it was suggested that AMVL elongation is a pri-
mary phenotypic expression of HCM. Several studies have 
indeed reported AMVL elongation in mutation carriers as 
measured by magnetic resonance imaging [6, 7, 10], and 
echocardiography [9]. The current study contradicts these 
findings. In line with our findings, a recent magnetic res-
onance imaging study similarly reported no difference in 
AMVL length between mutation carriers and controls [8]. 
The discrepancy between the studies may be related to the 
small number of participants, different imaging modalities 
Table 2  Baseline characteristics of HCM gene mutation carriers who 
did and did not develop hypertrophic cardiomyopathy during follow-
up
Data are expressed as mean ± standard deviation or as absolute and 
(%)
AMVL anterior mitral valve leaflet, A3C apical three chamber view, 
HCM hypertrophic cardiomyopathy, PLAX parasternal long axis view
Variable Developed HCM
Yes (n = 13) No (n = 77) p value
Age (years) 47 ± 19 39 ± 13 0.05
Male gender n (%) 8 (62) 25 (33) 0.04
Romhilt–Estes ≥ 4 n (%) 1 (8) 5 (7) 0.87
T wave inversion n (%) 1 (8) 0 (0) 0.01
Pathological Q n (%) 3 (23) 2 (3) 0.003
Left atrial size (mm) 39 ± 5 33 ± 5 <0.001
Maximal wall thickness (mm) 10 ± 2 9 ± 2 0.02
AMVL, PLAX (mm) 25 ± 5 24 ± 3 0.47
AMVL, A3C (mm) 29 ± 5 29 ± 4 0.90
Chordal systolic anterior motion 
n (%)
1 (8) 3 (4) 0.54
E/e’ ratio 9.3 ± 1.8 8.1 ± 1.7 0.03
Septal e’ (cm/s) 8.5 ± 2.7 9.5 ± 2.6 0.20
Abnormal diastolic function n 
(%)
4 (31) 11 (16) 0.21
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used, different distribution of genetic mutations, or different 
methodologies used for AMVL measurements.
For several reasons, we believe it is unlikely that HCM 
gene mutations cause AMVL elongation. First, there are no 
sarcomeric proteins in the mitral valve leaflet [25]. Second, 
a HCM animal model including heterozygous cardiac myo-
sin-binding protein C targeted knock-out mice embryos did 
not show mitral leaflet elongation [26]. Third, Captur et al. 
observed AMVL elongation in genotype-negative patients 
with HCM [10]. And finally, most morphological studies 
demonstrate that mitral leaflets are intrinsically normal [21, 
27]. Other potential etiologies of AMVL elongation are 
being investigated, such as the paracrine effects from the 
abnormal LV wall which influences valvulogenesis, or the 
abnormal differentiation of pluripotent epicardial-derived 
cells into fibroblast-cells with increased synthesis of peri-
ostin which might drive leaflet elongation [25].
Predicting the development of HCM
The current study demonstrates that AMVL length had 
no predictive value for the development of HCM. Hence, 
AMVL length cannot be used as a preclinical marker of the 
development of HCM. Similar observations were made in a 
prior smaller study by Ho et al. [28]. Pathological Q wave 
had a high predictive value for the development of HCM. 
Indeed, prior investigation of ECGs in genotyped HCM 
populations demonstrated that Q waves and repolarization 
abnormalities are the most distinguishing ECG manifesta-
tions of sarcomere mutations [29]. However, the clinical util-
ity of Q waves is probably limited because of the low nega-
tive predictive value; 10 out of 13 mutations that developed 
HCM did not have pathological Q waves at baseline. Our 
study did not demonstrate a prognostic value of septal e′, 
in contrast to Ho et al. [28]. The age difference between the 
studies (16 vs 41 years) and differences in genetic mutations 
might explain this discrepancy. However, we did observe a 
predictive value of E/e′ ratio, which supports the suggestion 
that diastolic dysfunction is a primary phenotypic feature 
of HCM [28, 30].
Technical challenges associated with AMVL 
measurement by echocardiography
Previous studies most commonly used magnetic resonance 
imaging to measure AMVL length [6–8, 10]. Since transtho-
racic echocardiography is the advised imaging modality in 
HCM clinical screening strategies and has a higher spatial 
and temporal resolution than cardiac magnetic resonance 
imaging [31, 32], we used echocardiography to determine 
AMVL length. Overall, inter-observer variability in both 
views was 2–3 mm, similar to previous studies [6, 8, 18]. 
The difference between observers may be explained by the 
technical difficulty of distinguishing the mitral leaflet from 
the chordae tendineae, and by the frame-to-frame variabil-
ity in AMVL length caused by AMVL movement during 
diastole and respiration. Intra-observer agreement was best 
for the A3C view, which was unexpected because in the 
PLAX view the distance to the transducer is shorter. It may 
be explained by the landmarks that were used; in the A3C 
view the insertion of the noncoronary aortic leaflet is more 
easily identifiable in comparison to the hinge point in the 
PLAX view. Finally, AMVL were significantly longer in the 
A3C view than in the PLAX view; the measurement in the 
A3C view included the intervalvular fibrosa.
Limitations
This study has several limitations. First, although the study 
population is large compared to previous studies, a higher 
sample size would reduce the risk of sampling error. Second, 
the proportion of HCM gene mutation carriers that devel-
oped HCM during follow-up was limited.
Conclusions
AMVL length is similar in HCM mutation carriers and 
healthy controls. AMVL length is not a predictor of the 
development of HCM during follow-up, in contrast to patho-
logical Q wave, E/e′ ratio, and maximal wall thickness.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual 
participants included in the study.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspec-
tives on the prevalence of hypertrophic cardiomyopathy. J Am 
Coll Cardiol 65(12):1249–1254
223Journal of Ultrasound (2018) 21:217–224 
1 3
 2. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, 
Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, 
McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper 
PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H 
(2014) ESC Guidelines on diagnosis and management of hyper-
trophic cardiomyopathy: the Task Force for the Diagnosis and 
Management of Hypertrophic Cardiomyopathy of the European 
Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779
 3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, 
Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman 
CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/
AHA guideline for the diagnosis and treatment of hypertrophic 
cardiomyopathy: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice 
Guidelines. J Thorac Cardiovasc Surg 142(6):e153–e203
 4. Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-
Zwarts KY, Pinto Y (2015) Genetic advances in sarcomeric car-
diomyopathies: state of the art. Cardiovasc Res 105(4):397–408
 5. Olivotto I, Cecchi F, Poggesi C, Yacoub MH (2012) Patterns of 
disease progression in hypertrophic cardiomyopathy: an individu-
alized approach to clinical staging. Circ Heart Fail 5(4):535–546
 6. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, 
Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ (2011) 
Mitral valve abnormalities identified by cardiovascular magnetic 
resonance represent a primary phenotypic expression of hyper-
trophic cardiomyopathy. Circulation 124(1):40–47
 7. Captur G, Lopes LR, Mohun TJ, Patel V, Li C, Bassett P, Finoc-
chiaro G, Ferreira VM, Esteban MT, Muthurangu V, Sherrid MV, 
Day SM, Canter CE, McKenna WJ, Seidman CE, Bluemke DA, 
Elliott PM, Ho CY, Moon JC (2014) Prediction of sarcomere 
mutations in subclinical hypertrophic cardiomyopathy. Circ Car-
diovasc Imaging 7(6):863–871
 8. Tarkiainen M, Sipola P, Jalanko M, Helio T, Laine M, Jarvinen 
V, Hayrinen K, Lauerma K, Kuusisto J (2016) Cardiovascular 
magnetic resonance of mitral valve length in hypertrophic car-
diomyopathy. J Cardiovasc Magn Reson 18(1):33
 9. Peyrou J, Reant P, Reynaud A, Cornolle C, Dijos M, Rooryck-
Thambo C, Landelle M, Montaudon M, Laurent F, Roudaut R, 
Lafitte S (2016) Morphological and functional abnormalities pat-
tern in hypertrophy-free HCM mutation carriers detected with 
echocardiography. Int J Cardiovasc Imaging 32(9):1379–1389
 10. Captur G, Lopes LR, Patel V, Li C, Bassett P, Syrris P, Sado DM, 
Maestrini V, Mohun TJ, McKenna WJ, Muthurangu V, Elliott PM, 
Moon JC (2014) Abnormal cardiac formation in hypertrophic car-
diomyopathy: fractal analysis of trabeculae and preclinical gene 
expression. Circ Cardiovasc Genet 7(3):241–248
 11. Cardim N (2017) Clinical detection of mutation carriers of hyper-
trophic cardiomyopathy in perspective: is cardiac imaging the 
crystal ball of the cardiologist? Eur Heart J Cardiovasc Imaging 
18(4):390–391
 12. van Velzen HG, Vriesendorp PA, Oldenburg RA, van Slegtenhorst 
MA, van der Velden J, Schinkel AF, Michels M (2016) Value of 
genetic testing for the prediction of long-term outcome in patients 
with hypertrophic cardiomyopathy. Am J Cardiol 118(6):881–887
 13. Michels M, Hoedemaekers YM, Kofflard MJ, Frohn-Mulder I, 
Dooijes D, Majoor-Krakauer D, Ten Cate FJ (2007) Familial 
screening and genetic counselling in hypertrophic cardiomyopa-
thy: the Rotterdam experience. Neth Heart J 15(5):184–190
 14. Menting ME, McGhie JS, Koopman LP, Vletter WB, Helbing 
WA, van den Bosch AE, Roos-Hesselink JW (2016) Normal 
myocardial strain values using 2D speckle tracking echocardi-
ography in healthy adults aged 20–72 years. Echocardiography 
33(11):1665–1675
 15. Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem 
B, Goldstein SA, Hung J, Maron MS, Ommen SR, Woo A (2011) 
American society of echocardiography clinical recommendations 
for multimodality cardiovascular imaging of patients with hyper-
trophic cardiomyopathy: endorsed by the American society of 
nuclear cardiology, society for cardiovascular magnetic resonance, 
and society of cardiovascular computed tomography. J Am Soc 
Echocardiogr 24(5):473–498
 16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, 
Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova 
T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski 
L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for 
cardiac chamber quantification by echocardiography in adults: 
an update from the American society of echocardiography and 
the European association of cardiovascular imaging. Eur Heart J 
Cardiovasc Imaging 16(3):233–270
 17. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, 
Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, 
Evangelisa A (2009) Recommendations for the evaluation of left 
ventricular diastolic function by echocardiography. Eur J Echocar-
diogr 10(2):165–193
 18. Klues HG, Proschan MA, Dollar AL, Spirito P, Roberts WC, 
Maron BJ (1993) Echocardiographic assessment of mitral valve 
size in obstructive hypertrophic cardiomyopathy. Anatomic vali-
dation from mitral valve specimen. Circulation 88(2):548–555
 19. Alhaj EK, Kim B, Cantales D, Uretsky S, Chaudhry FA, Sherrid 
MV (2013) Symptomatic exercise-induced left ventricular outflow 
tract obstruction without left ventricular hypertrophy. J Am Soc 
Echocardiogr 26(5):556–565
 20. Altman DG (1990) Practical Statistics for Medical Research. Tay-
lor & Francis Ltd, Milton Park
 21. Klues HG, Maron BJ, Dollar AL, Roberts WC (1992) Diversity of 
structural mitral valve alterations in hypertrophic cardiomyopathy. 
Circulation 85(5):1651–1660
 22. Kim DH, Handschumacher MD, Levine RA, Choi YS, Kim YJ, 
Yun SC, Song JM, Kang DH, Song JK (2010) In vivo meas-
urement of mitral leaflet surface area and subvalvular geom-
etry in patients with asymmetrical septal hypertrophy: insights 
into the mechanism of outflow tract obstruction. Circulation 
122(13):1298–1307
 23. Teo EP, Teoh JG, Hung J (2015) Mitral valve and papillary muscle 
abnormalities in hypertrophic obstructive cardiomyopathy. Curr 
Opin Cardiol 30(5):475–482
 24. Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG (2016) The 
Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: a Test 
in Context. J Am Coll Cardiol 67(15):1846–1858
 25. Levine RA, Hagege AA, Judge DP, Padala M, Dal-Bianco JP, 
Aikawa E, Beaudoin J, Bischoff J, Bouatia-Naji N, Bruneval P, 
Butcher JT, Carpentier A, Chaput M, Chester AH, Clusel C, Del-
ling FN, Dietz HC, Dina C, Durst R, Fernandez-Friera L, Hand-
schumacher MD, Jensen MO, Jeunemaitre XP, Le Marec H, Le 
Tourneau T, Markwald RR, Merot J, Messas E, Milan DP, Neri T, 
Norris RA, Peal D, Perrocheau M, Probst V, Puceat M, Rosenthal 
N, Solis J, Schott JJ, Schwammenthal E, Slaugenhaupt SA, Song 
JK, Yacoub MH, Leducq N (2015) Mitral transatlantic, mitral 
valve disease–morphology and mechanisms. Nat Rev Cardiol 
12(12):689–710
 26. Captur G, Ho CY, Schlossarek S, Kerwin J, Mirabel M, Wilson R, 
Rosmini S, Obianyo C, Reant P, Bassett P, Cook AC, Lindsay S, 
McKenna WJ, Mills K, Elliott PM, Mohun TJ, Carrier L, Moon 
JC (2016) The embryological basis of subclinical hypertrophic 
cardiomyopathy. Sci Rep 6:27714
 27. Teare D (1958) Asymmetrical hypertrophy of the heart in young 
adults. Br Heart J 20(1):1–8
 28. Ho CY, Cirino AL, Lakdawala NK, Groarke J, Valente AM, Sem-
sarian C, Colan SD, Orav EJ (2016) Evolution of hypertrophic 
cardiomyopathy in sarcomere mutation carriers. Heart. https ://
doi.org/10.1136/heart jnl-2016-31001 5
224 Journal of Ultrasound (2018) 21:217–224
1 3
 29. Lakdawala NK, Thune JJ, Maron BJ, Cirino AL, Havndrup O, 
Bundgaard H, Christiansen M, Carlsen CM, Dorval JF, Kwong 
RY, Colan SD, Kober LV, Ho CY (2011) Electrocardiographic 
features of sarcomere mutation carriers with and without 
clinically overt hypertrophic cardiomyopathy. Am J Cardiol 
108(11):1606–1613
 30. Kauer F, van Dalen BM, Michels M, Soliman OI, Vletter WB, 
van Slegtenhorst M, ten Cate FJ, Geleijnse ML (2013) Diastolic 
abnormalities in normal phenotype hypertrophic cardiomyopathy 
gene carriers: a study using speckle tracking echocardiography. 
Echocardiography 30(5):558–563
 31. Lin E, Alessio A (2009) What are the basic concepts of temporal, 
contrast, and spatial resolution in cardiac CT? J Cardiovasc Com-
put Tomogr 3(6):403–408
 32. To AC, Flamm SD, Marwick TH, Klein AL (2011) Clinical utility 
of multimodality LA imaging: assessment of size, function, and 
structure. JACC Cardiovasc Imaging 4(7):788–798
Affiliations
Hannah G. van Velzen1  · Arend F. L. Schinkel1 · Myrthe E. Menting1 · Annemien E. van den Bosch1 · 
Michelle Michels1
 * Hannah G. van Velzen 
 h.g.vanvelzen@erasmusmc.nl
1 Department of Cardiology, Thorax-center, Erasmus 
Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, 
The Netherlands
